The company - About us

The story about Rarity Bioscience

The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

Discovery in molecular biology

Rarity Bioscience was founded in 2021 as a spin out from Uppsala University to further develop and commercialize the superRCA assay technology. 

The superRCA technology was first discovered and developed in 2015 by PhD Lei Chen and Professor Ulf Landegren in the Molecular Tools group at the Department of Immunology, Genetics, and Pathology. The initial aim was to continue the successful development of padlock probe and rolling circle amplification to generate secondary rolling structures that could increase the signal intensity of existing protocols. 

Rarity Bioscience – the story

As with most scientific discoveries, the path is not always straight, but the superRCA came out as an extremely powerful amplification tool with unique allele distinction suitable for single variant mutation detection. 

The first application in Leukemia was studied together with Uppsala Academic Hospital and SciLifeLab during 2018-2020 as a retrospective benchmarking study that showed that the Rarity superRCA was able to detect common mutations in Acute myeloid leukemia (AML) with a greater sensitivity than current test practice i.e. ddPCR and NGS. In addition, a study of multiple follow-up samples showed that relapse could have been detected up to three months earlier. (Lei et al. Nature Communication)

Vision & Mission

Our vision is to democratize mutation detection.

Our mission is to improve clinical decisions and patient outcome by offering fast, sensitive, and reliable mutation detection technology at the right time.

Management Team

1JS9601-Linus-Bosaeus-sv-768x1024

Linus Bosaeus

CEO

Director of Operations (2019-2021) and VP Operations Clinical Trials (2021) at NuvoAir. Head of Development (2012-2016) and CEO (2016-2018) at Endovab. Research Engineer and FOI including risk management and long term planning. Board member at Endovab, and Muntra, a cloud based journal system for dental care.

1JS9594-Lei-Chen-sv-225x300

Lei Chen

CO-FOUNDER & CTO

Bachelor’s Degree in biotechnology (2004-2008) at Nanjing University, China. 
Master’s Degree in Applied Biotechnology (2008-2010) at Uppsala University, Sweden. 
Host seminars in Liquid Biopsy course at EMBL (2018-2021).
Active collaborations with the IVD industry on the consulting base.

  • PhD Molecular Tools, Uppsala University,
  • Inventor of the SafeLock technology
  • 10 years of experience in in vitro diagnostics
  • Inventor of 4 patents/applications
  • Five peer reviewed publications.
Hanna-Kocken-1-234x300

Hanna Kocken

HEAD OF QUALITY AND REGULATORY

Thermo Fisher Scientific (2022-2015): Senior Manager Research & Development, Acting Director Regulatory Affairs, Quality and Regulatory Lead. ÅF/AFRY (2015-2011): Product Compliance Consultant, assignments for IVD, Medical Device and Life Science business. Bactiguard (2011-2005): Quality System Manager, Technical Product Manager, Project Manager. MeTaCot (2005-2003): Research Engineer.

  • Master of Science, Engineering – Royal Institute of Technology
  • 20 years in Life Science and Medical Device industry
  • 10 years in Quality and Regulatory compliance positions
  • Extensive experience from Quality Management, Regulatory Compliance, Product Development and Cross Functional Leadership
alexander_rarity webb_gråskala

Alexander Kele

BUSINESS DEVELOPMENT DIRECTOR

Director Marketing at Vironova AB (2021-2022). Cytiva/GE Healthcare: Sr PM Life Sciences Digital at (2018-2021); Sr Global Product Manager Bioprocess (2015-2018); Market Development Leader Pharma (2014-2015); Global Marketing Manager (2011-2015). Attana AB: Global Product & Marketing Manager (2008-2011). Application and sales specialist (2007-2008).

 

  • PhD in molecular medicine and disease genetics, Karolinska Institutet
  • Master of Science in Biomedicine, Karolinska Institutet
  • 15+ years global experience serving in life science start-ups and global matrix organizations
  • Extensive experience from business strategy & development, product development & life cycle management, strategic & tactical marketing and sales.
  • Extensive experience from leading & developing high performing multifunctional and multicultural teams across multiple geographies.
  • Experience from hardware, software, consumables and cloud native products in GLP and GMP regulated environments.
  • Five peer review publications and five industrial white papers.
  • Co-inventor on 1 pending patent
  • Scientist at heart, businessman at mind

Board of Directors

Mikael-Smedeby

Mikael Smedeby

CO-FOUNDER, CHAIRMAN OF THE BOARD

General Counsel, Structures Freemont SA. Active as a lawyer since 1994. Member of the Swedish Bar Association. Executive positions at Advokatfirman Lindahl, including Managing Partner and Chairman of the Board. Member of the Board of Directors of BioArctic, 2014–2017. Special experience in corporate law, mergers and acquisitions, financing and licensing.

  • Master of Law, Uppsala University
  • Partner at Lindahl Law firm
  • Over 20 years of experience in capital markets, mergers & acquisitions
  • Vast experience as a board member in public listed companies and financial institutions.
  • Chairman of the Board of Coeli Holding AB and Sallengruppen AB (including subsidiaries)
  • Board member of Smedeby Förvaltning AB.
1JS9606-Ulf-LAndegren-225x300

Ulf Landegren

CO-FOUNDER & BOARD MEMBER

  • Professor of Molecular Medicine, Uppsala University
  • Invented 46 patents/applications
  • Research in his lab has resulted in 10 companies, including ParaAllele, Olink Bioscience (renamed Navinci), Halo Genomics, Q-linea, Olink Proteomics and Rarity Bioscience
  • Member of EMBO and the Royal Swedish Academy of Sciences
  • Former senior visiting scientist at Riken, Yokohama and a Fellow of School of Engineering at Tokyo University
1JS9598-Nils-Landegren-sv-225x300

Nils Landegren

BOARD MEMBER

  • MD, PhD, Uppsala University
  • Assistant Professor in Experimental Medical Genomics and group leader at Uppsala University
  • ERC Starting Grant recipient
  • Postdoc at Karolinska Institute, 2016-2020
  • Combined clinical and research internship in Uppsala, 2016-2018
1JS9586-Per-Matsson-sv-225x300

Per Matsson

CO-FOUNDER, DEPT CHAIRMAN OF THE BOARD

Head of R&D (immunology) at Sanofi Diagnostics Pasteur Inc. VP of R&D at Pharmacia Diagnostics AB, with development and registration of diagnostic products throughout the world including Europe, US and Japan.

  • MBA, PhD Biology SLU
  • Served as CSO of ThermoFisher ImmunoDiagnostics division (Phadia AB) for 9 years
  • Founder/co-founder of several early stage life science companies
  • Over 30 years of experience in IVD product development and the international Life Science industry, including R&D, medical and regulatory affairs, IP rights, strategy, mergers & acquisitions, and business development
  • Chairman of Scandinavian CLC board of EIT Health
  • Associate professor at Uppsala University and Swedish Agricultural University
1JS9590-Idar-Kreutzer-sv-225x300

Idar Kreutzer

BOARD MEMBER

Former member of the World Business Council for Sustainable Development (WBCSD) and has Co-Chaired their Vision 2050. Former member of The Norwegian Commission for Green Competitiveness (2015-2016). Appointed member of the Strategy Council for the Norwegian Government Pension Fund Global in 2013.

  • Master of Finance & Business NHH
  • Prior CEO of Storebrand and board member at several large corporations, including Hydor, Orkla, Norske Skog and more
  • CEO of Finance Norway
  • Member of the board at Aschehoug Forlag, NHH School of economics
  • Member of the Board of the University of Oslo
  • Member of The Minister of Climate and Environment’s Climate Policy Council, since 2014
  • Chairs the Nomination Committee at Orkla AS
  • Deputy Chairman of the Corporate Assembly of Statoil AS. Member of the Corporate Assembly of Norsk Hydro ASA
  • Member of the Strategy Council for the Norwegian Government Pension Fund Global since 2013
1JS9611-Ove-Öhman

Ove Öhman

ADVISOR

Former senior research fellow at J&J and Pharmacia. Serial Entrepreneur, with several successful ventures.

Career

Are you ready to join the future of precision diagnostics?

At Rarity Bioscience we are aiming at radically improving cancer diagnostic. We are developing a technology with the power of saving people’s lives. 

Our journey has just started, and we look forward to expand the team.

Join our vision to democratize mutation detection

Open positions at Rarity Bioscience

Unfortunately, we don’t have any open open positions at this time.

Follow us on LinkedIn to get the latest news and information about future career opportunities.